|Ms. Melanie Jaye Leydin C.A., B.Bus, CA||Joint Company Sec. & Director||N/A||N/A||1973|
|Dr. Adam William Darkins MB, ChB., MPHM, M.D., FRCS||Consultant||N/A||N/A||N/A|
|Mr. David B. Kaysen||Chairman, CEO & MD||N/A||N/A||1950|
|Ms. Peggy Morgan||Corp. Controller||N/A||N/A||N/A|
|Ms. Stephanie Ottens||Investor Relations Director||N/A||N/A||N/A|
Medibio Limited, a medical health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, and commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. Medibio Limited has a research agreement with the Department of Biomedical Sciences of Humanitas University for the development of mental health software products. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was founded in 1998 and is headquartered in Savage, Minnesota.
Medibio Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.